Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
--------------------------------------------------------------------
Source: CNBC
Published: 2026-07-10 20:09 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Economy & Finance, Financial Markets, Drugs, Business & Economy
--------------------------------------------------------------------
Snippet:
Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, CEO Marc de Garidel told CNBC after months of intense takeover speculation.
--------------------------------------------------------------------